Ivonescimab plus chemotherapy in advanced or metastatic non‐squamous non‐small cell lung cancer with EGFR variant in China: a cost‐effectiveness analysis
The findings indicate that for Chinese patients with nsq-NSCLC with EGFR who did not respond to EGFR-TKI therapy, the ivonescimab-chemotherapy combination is not cost-effective in the absence of price adjustment or any current charitable aid program.
Authors
- Qin Zhou (ORCID: https://orcid.org/0000-0003-3879-4021)
- Long Rong (ORCID: https://orcid.org/0000-0001-5450-0535)
- Weilu Kuang (ORCID: https://orcid.org/0000-0003-2601-9191)
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/tlcr-2024-1053
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04